FDA And EMA Approve AB Science's Phase 3 Masitinib Trial In MCRPC
4/7 08:25
(RTTNews) - AB Science (ABSCF.PK) announced FDA and EMA authorization of a confirmatory Phase 3 trial of masitinib in metastatic castrate-resistant prostate cancer, using a harmonized protocol and biomarker targeting patients with less advanced disease....